Growth of Toujeo has also stalled, with a rise of just over 1% compared to the same period of 2018 and a 25% decline in the US in the third quarter which the company says was caused by the ...

Toujeo, which provides a steady insulin release over 24 hours via a once-daily injection, has become an essential solution for individuals with type 1 and type 2 diabetes. Its efficacy in ...